Sipuleucel-T

Key takeaways

Sipuleucel-T belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Sipuleucel-T to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Sipuleucel-T from memory before moving on to harder problems.

Reference excerpt

Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is an autologous cellular immunotherapy.

Medical uses Sipuleucel-T is indicated for the treatment of metastatic, asymptomatic or minimally symptomatic, metastatic castrate-resistant hormone-refractory prostate cancer (HRPC). Other names for this stage are metastatic castrate-resistant (mCRPC) and androgen independent (AI) or (AIPC). This stage leads to mCRPC with lymph node involvement and distal (distant) tumors; this is the lethal stage of CaP. The prostate cancer staging designation is T4,N1,M1c.

Treatment method A course of treatment consists of three basic steps:

The patient's white blood cells, primarily dendritic cells, a type of antigen-presenting cells (APCs), are extracted in a leukapheresis procedure. The blood product is sent to a production facility and incubated with a fusion protein (PA2024) consisting of two parts: The antigen prostatic acid phosphatase (PAP), which is present in 95% of prostate cancer cells and An immune signaling factor granulocyte-macrophage colony stimulating factor (GM-CSF) that helps the APCs to mature. The activated blood product (APC8015) is returned from the production facility to the infusion center and reinfused into the patient. Premedication with acetaminophen and antihistamine is recommended to minimize side effects.

Side effects Common side effects include: bladder pain; bloating or swelling of the face, arms, hands, lower legs, or feet; bloody or cloudy urine; body aches or pain; chest pain; chills; confusion; cough; diarrhea; difficult, burning, or painful urination; difficulty with breathing; difficulty with speaking up to inability to speak; double vision; sleeplessness; and inability to move the arms, legs, or facial muscles.

Society and culture

Legal status Sipuleucel-T was approved by the US Food and Drug Administration (FDA) in April 2010, to treat asymptomatic or minimally symptomatic metastatic HRPC. Sipuleucel-T was added to the compendium of cancer treatments as a "category 1" (highest recommendation) treatment for HRPC. The National Comprehensive Cancer Network (NCCN) Compendium is used by Medicare and major health care insurance providers to decide whether a treatment should be reimbursed.

Research

Clinical trials

Completed Sipuleucel-T showed overall survival (OS) benefit to patients in three double-blind randomized phase III clinical trials, D9901, D9902a, and IMPACT. The IMPACT trial served as the basis for FDA licensing. This trial enrolled 512 patients with asymptomatic or minimally symptomatic metastatic HRPC randomized in a 2:1 ratio. The median survival time for sipuleucel-T patients was 25.8 months comparing to 21.7 months for placebo-treated patients, an increase of 4.1 months. 31.7% of treated patients survived for 36 months vs. 23.0% in the control arm.

Ongoing As of August 2014, the PRO Treatment and Early Cancer Treatment (PROTECT) trial, a phase IIIB clinical trial started in 2001, was tracking subjects but no longer enrolling new subjects. Its purpose is to test efficacy for patients whose CaP is still controlled by either suppression of testosterone by hormone treatment or by surgical castration. Such patients have usually failed primary treatment of either surgical removal of the prostate, (EBRT), internal radiation, BNCT or (HIFU) for curative intent. Such failure is called biochemical failure and is defined as a PSA reading of 2.0 ng/mL above nadir (the lowest reading taken post primary treatment). As of August 2014, a clinical trial administering sipuleucel-T in conjunction with ipilimumab (Yervoy) was tracking subjects but no longer enrolling new subjects; the trial evaluates the clinical safety and anti-cancer effects (quantified in PSA, radiographic and T cell response) of the combination therapy in patients with advanced prostate cancer. Results from the large PROCEED registry, which enrolled men between 2011 and 2017, showed that men with metastatic castration-resistant prostate cancer had a median overall survival of approximately 30.7 months from the date of treatment, and that people with lower PSA levels had longer survival. Research also found that African American men treated with Sipuleucel-T had similar or sometimes better survival than non-African American men, along with stronger immune activity, including higher levels of immune markers like ICOS, GM-CSF, CCL4 and CCL5. These immune markers fit with the treatment's ability to stimulate antigen-presenting cells and downstream T-cell activity.

References

This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.

Worked examples

Example 1 — a first encounter with Sipuleucel-T

Start with the simplest possible case. Write down what Sipuleucel-T claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Sipuleucel-T before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Sipuleucel-T ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Sipuleucel-T

In research: Sipuleucel-T appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Sipuleucel-T in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Sipuleucel-T is common in secondary-school and first-year university syllabi. It links to neighbouring topics Cancer treatments, Cell therapies, Prostate cancer, so understanding it makes those chapters shorter.
In everyday life: Look for Sipuleucel-T outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

How to study Sipuleucel-T in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Sipuleucel-T means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Sipuleucel-T out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Sipuleucel-T in simple terms?

Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is an autologous cellular immunotherapy.

Why does Sipuleucel-T matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Sipuleucel-T?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Sipuleucel-T.